Impact of Chemotherapy Beyond the Third Line in Patients With Recurrent Epithelial Ovarian Cancer.

Fiche publication


Date publication

février 2016

Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc, Pr NERICH Virginie, Pr PIVOT Xavier, Dr MANSI Laura, Dr THIERY-VUILLEMIN Antoine, Dr DEMARCHI Martin, Dr LAKKIS Zaher


Tous les auteurs :
Mansi L, Demarchi M, Bazan F, Delroeux D, Chaigneau L, Thiery-Vuillemin A, Bernhard S, Lakkis Z, Lakkis Z, Nerich V, Pivot X, Kalbacher E

Résumé

The goal of this study was to determine the benefit in terms of time disease control (TDC) achieved by the succession of chemotherapy beyond the third line in patients treated for recurrent epithelial ovarian cancer. Secondary objectives were to identify patients who benefited from treatments beyond 3 lines and to estimate overall survival and disease-free progression lengths.

Mots clés

Adult, Aged, Aged, 80 and over, Antineoplastic Agents, administration & dosage, Female, Humans, Middle Aged, Neoplasms, Glandular and Epithelial, drug therapy, Ovarian Neoplasms, drug therapy, Retrospective Studies

Référence

Int. J. Gynecol. Cancer. 2016 Feb;26(2):261-7